13Jul 2023
SII, PATH meningococcal meningitis conjugate vaccine receives WHO prequalification

SII, PATH meningococcal meningitis conjugate vaccine receives WHO prequalification

Serum Institute of India Pvt Ltd (SII) and PATH have achieved a major milestone with the prequalification of MenFive, the first conjugate vaccine to protect against the five major causes of meningococcal meningitis in Africa, by the WHO. The 13-year collaboration, supported by the UK government, aims to eliminate annual meningitis outbreaks in the African meningitis belt. MenFive protects against meningococcal serogroups A, C, W, Y, and X and has demonstrated high levels of safety and efficacy in clinical studies.

  • #family health

Like

Save

Share